Journals / Diagnostic and Interventional Radiology / 2022 / Cilt: 28 - Sayı: 1

Thoracic CT radiomics analysis for predicting synchronous brain metastasis in patients with lung cancer

Pages
39–49
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, the radiomics model can also be utilized as an indicator for identifying oligometastatic or multiple brain metastases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE We aimed to assess the feasibility of radiomics analysis based on non-contrast-enhanced thoracic CT images in predicting synchronous brain metastasis (SBM) in lung cancer patients at initial diagnosis.
📊
Key Findings & Data:METHODS This retrospective study enrolled 371 lung cancer patients (with SBM n=147, without SBM n=224) confirmed by histopathology.
💡
Conclusion & Impact:Furthermore, the radiomics model can also be utilized as an indicator for identifying oligometastatic or multiple brain metastases.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PURPOSE We aimed to assess the feasibility of radiomics analysis based on non-contrast-enhanced thoracic CT images in predicting synchronous brain metastasis (SBM) in lung cancer patients at initial diagnosis. METHODS This retrospective study enrolled 371 lung cancer patients (with SBM n=147, without SBM n=224) confirmed by histopathology. Patients were allocated to the training set (n=258) and testing set (n=113). The optimal radiomics features were selected by using the least absolute shrinkage and selection operator (LASSO) algorithm. The radiomics, clinicoradiologic, and combined models were developed to predict SBM using multivariable logistic regression. Then the discrimination ability of the models was assessed. Furthermore, the prediction performance of the abovementioned three models for oligometastatic (1-3 lesions) or multiple (>3 lesions) brain metastases in SBM, metachronous brain metastasis (MBM), and total (SBM and MBM) groups were investigated. RESULTS Six radiomics features and two clinicoradiologic characteristics were chosen for predicting SBM. Both the radiomics model (area under the receiver operating characteristic curve [AUC] = 0.870 and 0.824 in the training and testing sets, respectively) and the combined model (AUC = 0.912 and 0.859, respectively) presented better predictive ability for SBM than the clinicoradiologic model (AUC = 0.712 and 0.692, respectively). The decision curve analysis (DCA) demonstrated the clinical usefulness of the radiomics-based models. The radiomics model can also be used to predict oligometastatic or multiple brain metastases in SBM, MBM, and total groups (P = .045, P = .022, and P = .030, respectively). CONCLUSION The radiomics model and the combined model can be used as valuable imaging markers for predicting patients at high risk of SBM at the initial diagnosis of lung cancer. Furthermore, the radiomics model can also be utilized as an indicator for identifying oligometastatic or multiple brain metastases.

🔖

Cite This Article

JU, S., DING, Z., WANG, Y., XIA, C., MENG, X., YU, Q. (2022). Thoracic CT radiomics analysis for predicting synchronous brain metastasis in patients with lung cancer. Diagnostic and Interventional Radiology, Cilt: 28 - Sayı: 1, 39–49. https://ajindex.com/articles/487235

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2021
  2. [Crossref] 2. Dragoj M, Milosevic Z, Bankovic J, et al. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in nonsmall cell lung carcinoma. Cell Oncol (Dordr). 2017
  3. [Crossref] 3. Yang L, Li J, Fu S, et al. Up-regulation of insulin-like growth factor binding protein-3 is associated with brain metastasis in lung adenocarcinoma. Mol Cells. 2019
  4. Nolan C, Deangelis LM. Overview of metastatic disease of the central nervous system. Handb Clin Neurol. 2018
  5. [Crossref] 5. Soffietti R, Cornu P, Delattre JY, et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006
  6. [Crossref] 6. Budczies J, von Winterfeld M, Klauschen F, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015
  7. [Crossref] 7. Thomas AJ, Rock JP, Johnson CC, et al. Survival of patients with synchronous brain metastases: an epidemiological study in southeastern Michigan. J Neurosurg. 2000
  8. [Crossref] 8. Shibahara I, Kanamori M, Watanabe T, et al. Clinical Feature s of precocious, synchronous, and metachronous brain metastases and the role of tumor resection. World Neurosurg. 2018
  9. e1-e9. [Crossref] 9. Ali A, Goffin JR, Arnold A, et al. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013
  10. e300-306. [Crossref] 10. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017
  11. [Crossref] 11. Sánchez de Cos J, Sojo González MA, Montero MV, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009
  12. [Crossref] 12. Hochstenbag MM, Twijnstra A, Wilmink JT, et al. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000
  13. [Crossref] 13. Chen XR, Hou X, Li DL, et al. Management of non-small-cell lung cancer patients initially diagnosed with 1 to 3 synchronous brain-only metastases: a retrospective study. Clin Lung Cancer. 2020
  14. e25-34. [Crossref] 14. Amin MB, Edge S, Greene F, et al